Maturitas
Volume 60, Issue 1 , Pages 10-18 , 20 May 2008

Metabolic syndrome after menopause and the role of hormones

Received 9 November 2007 ,Revised 22 January 2008 ,Accepted 6 February 2008.

References 

  1. In: WHO European Ministerial Conference on Counteracting Obesity. World Health Organization. 2007;
  2. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive Summary of the Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001;285: 2486–97.
  3. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709–2716
  4. Ford ES, Giles WH, dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–359
  5. Park YW, Zhu S, Palaniappa L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2003;163(4):427–436
  6. Sowers MF, Zheng , Tomey K, et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab. 2007;92(3):895–901
  7. Chu MC, Cosper P, Orio F, et al. Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, resistin, and ghrelin. Am J OB/GYN. 2006;194:100–104
  8. Norata GD, Raselli S, Grigore L, et al. Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke. 2007;(epub ahead of print)
  9. Behre CJ. Adiponectin, obesity and atherosclerosis. Scand J Clin Lab Invest. 2007;67(5):449–458
  10. Salpeter SR, Walsh JME, Ormiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women.. Diabetes, Obesity Metabol. 2006;8:538–554
  11. O'sullivan AJ, Crampton LI, Freund J, et al. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest. 1998;102:1035–1040
  12. Ho KK, O'Sullivan AJ, Wolthers T, et al. Metabolic effects of oestrogens: impact of the route of administration. Ann Endocrinol (Paris). 2003;64:170–177
  13. dos Reis CM, de Melo NR, Meirelles ES, et al. Body composition, visceral fat distribution and fat oxidation in postmenopausal women using oral or transdermal oestrogen. Maturitas. 2003;46:59–68
  14. Di Carlo C, Tommaselli GA, Sammartino A, et al. Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy. Menopause. 2004;11:466–473
  15. Chu MC, Cosper P, Nakhuda G, et al. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertil Steril. 2006;86(6):1669–1675
  16. Lindheim SR, Presser SC, Ditkoff EC, et al. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril. 1993;60:664–667
  17. Lindheim SR, Duffy DM, Kojima T, et al. The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. Fertil Steril. 1994;62:1176–1180
  18. Cucinelli F, Paparella P, Soranna L, et al. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. Eur J Endocrinol. 1999;140:215–223
  19. Konayn AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1–9
  20. Margolis KL, Bonds DE, Rodabough RI, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the women's health initiative hormone trial. Diabetologia. 2004;47:1175–1187
  21. Ferrara A, Karter AJ, Ackerson LM, et al. Hormone replacement therapy is associated with better glycemic control in women: the Northern California Kaiser Permanente Diabetes Registry. Diabetes Care. 2001;24(7):1144–1150
  22. Friday KE, Dong C, Fontenot RU. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2001;86(1):48–52
  23. Chu M, Cushman M, Solomon R, Lobo RA. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation. Presented at Society of Gynecological Investigation 2006.
  24. Sumino H, Ichikawa S, Kasama S, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis. 2006;189:436–442
  25. Mueck AO, Genazzani AR, Samsioe G, et al. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Menopause. 2007;14(6):1–7
  26. Lewandowski KC, Komorowski J, Mikhalidis DP, et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab. 2006;91(8):3123–3130
  27. Sumino H, Ichikawa S, Kasama S, et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens Res. 2005;28(7):579–584
  28. Lacut K, Oger E, LeGel G, et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost. 2003;90(1):124–131
  29. The Writing Group for, PEPI. JAMA. 1994;273:199–208
  30. Koh KK, Yoon R-K, Merz CN, et al. The effects of hormone therapy on inflammatory, hemostatic and fibrinolytic markers in postmenopausal women. In:  Lobo RA editors. Treatment of the postmenopausal woman, basic and clinical aspects. Third edition. Elsevier; 2007;p. 471–480
  31. Scarabin PY, Oger E, Plu-Bueau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428–432
  32. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Circulation. 2007;115:840–845
  33. Oger E, Martine A-G, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women.. Arteriosc, Thromb Vasc Biol. 2003;23:1671–1676
  34. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–1477
  35. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol. 2000;36(6):1797–1802

PII: S0378-5122(08)00039-X

doi: 10.1016/j.maturitas.2008.02.008

Maturitas
Volume 60, Issue 1 , Pages 10-18 , 20 May 2008

Article Tools

* Image Usage & Resolution